2022
The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey.
Reynolds L, Barnett B, Weleff J, Morunga E, Wells A, Stack A, Akroyd A, Hoeh N, Sundram F, Muthukumaraswamy S, Lawrence N, Evans W. The perceptions of cancer health-care practitioners in New Zealand and the USA toward psychedelic-assisted therapy with cancer patients: A cross-sectional survey. Palliative & Supportive Care 2022, 22: 664-673. PMID: 36325995, DOI: 10.1017/s1478951522001481.Peer-Reviewed Original ResearchHealth-care practitionersCross-sectional surveyPsychedelic-assisted therapyPatients to trialsIndigenous perspectives of healthEnd-of-life contextCancer patientsEnd-of-lifePerspective of healthVulnerable cancer patientsMind-altering experiencesNew Zealand participantsExistential distressConvenience sampleNew ZealandPsychedelic treatmentParticipantsPractitionersNew Zealand samplePerceptionCancerPatientsZealandAdvanced diseaseTrials
2021
United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020
Barnett B, Parker S, Weleff J. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006–2020. International Journal Of Drug Policy 2021, 99: 103473. PMID: 34624734, DOI: 10.1016/j.drugpo.2021.103473.Peer-Reviewed Original ResearchConceptsNational Institutes of HealthNational Institutes of Health grantsPsychedelic-assisted therapyResearch funding bodiesClinical trialsPublic funder of biomedical researchMental health conditionsNational Institutes of Health fundingNational Institutes of Health RePORTERFunding bodiesUnited States National Institutes of HealthSchedule 1 drugFunder of biomedical researchInstitutes of HealthFunding clinical trialsNIH grant supportHealth conditionsPsychedelic renaissanceUnited KingdomGrant fundingGrant databasesStudy periodPublic funders